Feature Channels: Clinical Trials

Filters close
Newswise: New intranasal vaccine platform provides potential for more effective vaccines with fewer side effects
6-Aug-2020 8:00 AM EDT
New intranasal vaccine platform provides potential for more effective vaccines with fewer side effects
University of Chicago Medical Center

A new study at the University of Chicago and Duke University finds that a new type of intranasal vaccine induces a strong immune response in lungs, with possible implications for COVID-19. The system uses nanofibers tagged with antigens to prime the immune system against a potential invasion.

access_time Embargo lifts in 2 days
Embargo will expire: 11-Aug-2020 11:00 AM EDT Released to reporters: 6-Aug-2020 1:40 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 11-Aug-2020 11:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Newswise: Imitation May Be a Sincere Form of Treatment
Released: 5-Aug-2020 12:35 PM EDT
Imitation May Be a Sincere Form of Treatment
University of California San Diego Health

The National Institutes of Health will soon launch a phase II clinical trial to evaluate the safety and efficacy of potential new therapeutics for COVID-19, including the use of investigational synthetic monoclonal antibodies. Davey Smith of UC San Diego is the protocol chair and answers questions.

Released: 5-Aug-2020 12:00 PM EDT
Study Reveals New Targets for Next-Generation COVID-19 Vaccines and Tests, Beyond Antibodies
Atlantic Health System

This clinical trial increased an understanding of how T cells mount a response to COVID-19 infection. These findings pave the way for diagnostic tests that detect COVID immunity based on T cells instead of antibodies. Research demonstrates that generating neutralizing antibodies rather than T cells, may not be sufficient for long-term immunity. New discoveries suggest that vaccines will need to incorporate T cell targets to generate lasting COVID-19 immunity.

Released: 4-Aug-2020 11:55 AM EDT
ACTG Announces Launch of Novel Clinical Trial Testing Multiple Therapeutics to Treat COVID-19
University of California, Los Angeles (UCLA), Health Sciences

The AIDS Clinical Trials Group (ACTG) has initiated the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial. ACTIV-2 includes both phase 2 and phase 3 evaluations of multiple promising investigational agents for treating early COVID-19 in a single trial.

Newswise: Tackling the Bioethics Challenges Raised by COVID-19
Released: 3-Aug-2020 3:05 PM EDT
Tackling the Bioethics Challenges Raised by COVID-19
University of Pennsylvania School of Nursing

The diverse situations experienced by health-care workers during the COVID-19 pandemic often present serious ethical challenges. From the allocation of resources and triage protocols to health-care worker and patient rights and the management of clinical trials, new ethical questions have come to the forefront of today’s global public health emergency.

Newswise:Video Embedded a-blood-test-could-predict-who-benefits-from-immunotherapy
VIDEO
Released: 3-Aug-2020 1:00 PM EDT
A blood test could predict who benefits from immunotherapy
University Health Network (UHN)

A test which detects changing levels of tumour fragments in the blood may be an easy, non-invasive and quick way to predict who will benefit from immunotherapy, a treatment option for advanced cancers.

Newswise: Important Dementia Studies Continuing at UK Despite Ongoing COVID-19 Pandemic
Released: 3-Aug-2020 10:20 AM EDT
Important Dementia Studies Continuing at UK Despite Ongoing COVID-19 Pandemic
University of Kentucky

The COVID-19 pandemic brought many things to a screeching halt and continues to impact our daily lives. However, important research at the University of Kentucky’s Sanders-Brown Center on Aging (SBCoA) is continuing under extreme caution and deep dedication. A monumental study in the field of dementia research is set to get underway in the coming weeks at UK.

Released: 31-Jul-2020 4:40 PM EDT
No racial disparities seen in response to remdesivir treatment of COVID-19
University of Chicago Medical Center

A new analysis by University of Chicago Medicine faculty, staff and collaborators around the world found remdesivir appears to be equally beneficial to patients regardless of race, supporting the need for early intervention and aggressive care for all patients in the fight against COVID-19.

Newswise:Video Embedded johns-hopkins-receives-35-million-in-funding-from-department-of-defense-for-covid-19-blood-plasma-trials
VIDEO
Released: 30-Jul-2020 10:00 AM EDT
Johns Hopkins Receives $35 Million in Funding from Department of Defense for Covid-19 Blood Plasma Trials
Johns Hopkins Medicine

Johns Hopkins researchers have received $35 million in funding from the U.S. Department of Defense (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), on behalf of the Defense Health Agency, for two nationwide clinical trials to test the effectiveness of a convalescent blood plasma outpatient treatment. The treatment is a transfusion of a blood product from COVID-19 survivors that contains antibodies that may help the patient’s immune system fight the virus.

Released: 30-Jul-2020 9:00 AM EDT
Study Suggests New Approach to Improve Radiation Therapy Resistance in Glioblastoma
Michigan Medicine - University of Michigan

Laboratory research paves the way for a clinical trial to see if an FDA-approved drug used to prevent organ transplant rejection can work against glioblastoma, a type of aggressive brain tumor.

Newswise: Single-shot COVID-19 vaccine protects non-human primates
Released: 30-Jul-2020 8:05 AM EDT
Single-shot COVID-19 vaccine protects non-human primates
Beth Israel Deaconess Medical Center

A leading COVID-19 vaccine candidate developed at Beth Israel Deaconess Medical Center creates the groundwork for a newly launched COVID-19 vaccine clinical trial

Released: 29-Jul-2020 10:50 AM EDT
Researchers Optimistic After Dose-Determining Trial of Compound Against Metastatic Castration-Resistant Prostate Cancer
Michigan Medicine - University of Michigan

A multi-institution phase 1b/2a clinical trial found good tolerability and encouraging efficacy data for a pan-BET bromodomain inhibitor in combination with enzalutamide.

Released: 29-Jul-2020 8:55 AM EDT
Cancer Research Institute and The Mark Foundation for Cancer Research Launch Collaboration to Evaluate Liquid Biopsy for More Accurate and Rapid Assessment of Lung Cancer Patient Response to Immunotherapy
The Cancer Research Institute (CRI) and The Mark Foundation for Cancer Research

The Cancer Research Institute (CRI) and The Mark Foundation for Cancer Research have launched a clinical trial that aims to demonstrate the utility of a novel, ultra-sensitive biomarker-directed blood test, or liquid biopsy, in assessing cancer patient responses to immunotherapy.

Newswise: BioMed Valley Discoveries’ ulixertinib (BVD-523), a first-in-class ERK inhibitor cancer therapy, receives Fast Track designation and launches Phase II trial in collaboration with Cmed and Strata Oncology
Released: 28-Jul-2020 12:15 PM EDT
BioMed Valley Discoveries’ ulixertinib (BVD-523), a first-in-class ERK inhibitor cancer therapy, receives Fast Track designation and launches Phase II trial in collaboration with Cmed and Strata Oncology
BioMed Valley Discoveries

BioMed Valley Discoveries (BVD), a clinical stage biotechnology company, announces the receipt of Fast Track designation from the US Food and Drug Administration (FDA) for investigation of the ERK inhibitor ulixertinib (BVD-523) as a treatment for patients with non-colorectal, solid tumors that harbor BRAF mutations G469A/V, L485W, or L597Q. BVD has launched a Phase II multi-center study of ulixertinib for patients with advanced malignancies harboring these atypical (non-V600) BRAF alterations or a MEK alteration.

Released: 27-Jul-2020 11:10 AM EDT
George Washington University to Conduct Clinical Trial for COVID-19 Experimental Vaccine
George Washington University

The George Washington University will participate in a clinical trial for an investigational COVID-19 vaccine.

Released: 24-Jul-2020 3:10 PM EDT
Dana-Farber to offer first CAR T-cell therapy for mantle cell lymphoma following FDA approval
Dana-Farber Cancer Institute

Today’s Food and Drug Administration (FDA) approval of the first CAR T-cell therapy for mantle cell lymphoma (MCL) represents a key advance for patients with relapsed or treatment-resistant forms of the disease, say Dana-Farber Cancer Institute investigators who helped conduct the decisive clinical trial of the therapy.

Newswise: Baylor Scott & White Research Institute Expands Efforts in the Fight Against COVID-19
Released: 24-Jul-2020 11:40 AM EDT
Baylor Scott & White Research Institute Expands Efforts in the Fight Against COVID-19
Baylor Scott and White Health

As the global response to the SARS-COV-2 virus that causes COVID-19 approaches 200 days, Baylor Scott & White Research Institute, the research and development arm of Baylor Scott & White Health, is accelerating its pace of bringing clinical trials online. Baylor Scott & White Research Institute continues to mobilize staff and resources, including components needed to integrate critical patient-safety measures at every participating site within the Baylor Scott & White system for industry sponsored drug trials, investigator-initiated drug trials and research studies, and observational and data studies designed to help increase knowledge around case trends, viral epidemiology, and care best practices.

Newswise: National Clinical Trial Launches, Will Test Promising Vaccine Against Novel Coronavirus
Released: 24-Jul-2020 11:20 AM EDT
National Clinical Trial Launches, Will Test Promising Vaccine Against Novel Coronavirus
University of California San Diego Health

UC San Diego Health and the Altman Clinical and Translational Research Institute will be sites for an accelerated national clinical trial to assess the efficacy and immunogenicity of a vaccine intended to protect against SARS-CoV-2, the coronavirus that causes COVID-19.

Released: 23-Jul-2020 5:05 PM EDT
Excellent Research Results for CAR-T Cell Therapy Against Hodgkin Lymphoma
University of North Carolina School of Medicine

CAR-T cell therapy, which attacks cancer cells using a person’s reprogrammed immune cells, has been used to treat Hodgkin lymphoma with remarkable success for the first time, according to the results of an early phase clinical trial.

Newswise: Cancer Clinical Trials Tested, Continue During COVID-19 Pandemic
Released: 23-Jul-2020 2:05 PM EDT
Cancer Clinical Trials Tested, Continue During COVID-19 Pandemic
University of California San Diego Health

During the COVID-19 pandemic, Moores Cancer Center at UC San Diego Health continues to offer potentially lifesaving treatment through cancer clinical trials.

Newswise: 2 immunotherapies merged into single, more effective treatment
Released: 23-Jul-2020 12:25 PM EDT
2 immunotherapies merged into single, more effective treatment
Washington University in St. Louis

Researchers at Washington University School of Medicine in St. Louis have combined two immunotherapy strategies into a single therapy and found, in studies in human cells and in mice, that the two together are more effective than either alone in treating certain blood cancers, such as leukemia.

Released: 22-Jul-2020 3:10 PM EDT
Patients who lived longer with cancer at greater risk of severe COVID-19 infection
King's College London

Cancer patients diagnosed more than 24 months ago are more likely to have a severe COVID-19 infection, research has found.

Newswise: Virginia Tech, partners launch nation’s first pediatric rehabilitation resource center
Released: 20-Jul-2020 7:40 PM EDT
Virginia Tech, partners launch nation’s first pediatric rehabilitation resource center
Virginia Tech

Research partners across three institutions are opening the nation’s first and only resource center dedicated to promoting clinical trials research in the rapidly expanding field of pediatric rehabilitation. It will be one of a network six centers under the umbrella of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, part of the National Institutes of Health, with direct oversight from the National Center for Medical Rehabilitation Research.

Newswise: UC Davis Health tests monoclonal antibodies as potential COVID-19 treatment
Released: 20-Jul-2020 2:35 PM EDT
UC Davis Health tests monoclonal antibodies as potential COVID-19 treatment
UC Davis Health

Timothy Albertson has received a BARDA grant to lead a new clinical trial at UC Davis Health. The trial evaluates the efficacy, safety and tolerability of an antibody cocktail in hospitalized adult patients with COVID-19.

Released: 20-Jul-2020 11:25 AM EDT
Despite Promising Lab Results, Most Precision Medicine Therapies for Mesothelioma Fail in the Clinical Setting
Sbarro Health Research Organization (SHRO)

Malignant mesothelioma (MM) is a lethal cancer mainly caused by exposure to asbestos, for which, unfortunately, no current treatment has proven effective, despite the identification of several promising therapeutic targets over the years.

Newswise: UM to Launch COVID-19 Vaccine Testing Site for the COVID-19 Prevention Trials Network
Released: 17-Jul-2020 3:45 PM EDT
UM to Launch COVID-19 Vaccine Testing Site for the COVID-19 Prevention Trials Network
University of Miami Health System, Miller School of Medicine

The University of Miami Miller School of Medicine has been selected to be part of the National Institutes of Health COVID-19 Prevention Trials Network (CoVPN) to launch clinical trials to test investigational COVID-19 vaccines.

Newswise: kalpna-gupta-1-copy.jpg
Released: 17-Jul-2020 12:40 PM EDT
Cannabis shows potential for mitigating sickle cell disease pain
University of California, Irvine

Cannabis appears to be a safe and potentially effective treatment for the chronic pain that afflicts people with sickle cell disease, according to a new clinical trial co-led by University of California, Irvine researcher Kalpna Gupta and Dr. Donald Abrams of UC San Francisco. The findings appear in JAMA Network Open.

Newswise:Video Embedded latest-developments-on-cytoreductive-surgery-hyperthermic-intraperitoneal-chemotherapy-crthipec
VIDEO
Released: 17-Jul-2020 7:15 AM EDT
Latest developments on Cytoreductive Surgery & Hyperthermic Intraperitoneal Chemotherapy (CRT/HIPEC)
Mercy Medical Center

Mercy Medical Center is the first institution in the United States to study the role of CRS/HIPEC for newly diagnosed with ovarian, fallopian tube, or primary peritoneal cancers. Literature exists involving CRS/HIPEC in the role of recurrent disease and in the neoadjuvant setting; however, there is no published data on the role as a primary treatment option in the United States.

Newswise: Use of Pembrolizumab Provided Long-Term Benefits in Patients With Metastatic Melanoma, 10-Year Look Shows
Released: 16-Jul-2020 4:05 PM EDT
Use of Pembrolizumab Provided Long-Term Benefits in Patients With Metastatic Melanoma, 10-Year Look Shows
Roswell Park Comprehensive Cancer Center

A new 10-year analysis led by Igor Puzanov, MD, MSci, FACP, Director of Early Phase Clinical Trials and Chief of Melanoma at Roswell Park Comprehensive Cancer Center and published today in the journal JAMA Oncology provides new insights into an important question: whether BRAF V600E/K mutation status or previous BRAF inhibitor (BRAFi) therapy with or without a MEK inhibitor (MEKi) affects response to pembrolizumab (brand name Keytruda) in patients with advanced melanoma.

Newswise: New Advances Provide Hope for Alzheimer's Patients
Released: 16-Jul-2020 4:05 PM EDT
New Advances Provide Hope for Alzheimer's Patients
University of Nevada, Las Vegas (UNLV)

Dr. Jeffrey L. Cummings, UNLV research professor and a leading expert on Alzheimer’s disease clinical trials, led a five-year review of all Alzheimer’s drugs in the development pipeline. He says today there is more hope than ever that we'll one day solve Alzheimer’s. The paper, “Alzheimer's disease drug development pipeline: 2020,” was published this week in the journal Alzheimer's & Dementia: Translational Research & Clinical Interventions.

Newswise: 237541_web.jpg
Released: 15-Jul-2020 3:45 PM EDT
Scientists discover way to stop spread of devastating childhood cancer
University of East Anglia

Researchers at the University of East Anglia and University of Manchester have made an important breakthrough that could lead to 'kinder' treatments for children with bone cancer, and save lives.

Newswise: Yale Cancer Center Receives NCI Grant Renewal to Fund Clinical Trials
Released: 15-Jul-2020 12:05 PM EDT
Yale Cancer Center Receives NCI Grant Renewal to Fund Clinical Trials
Yale Cancer Center

The National Cancer Institute has awarded a UM1 grant renewal to Yale Cancer Center. The 6-year, $3 million a year grant will fund early phase investigator-initiated clinical trials to develop new potential therapies for treating both solid tumors and hematologic malignancies.

Released: 15-Jul-2020 8:35 AM EDT
NCCN Explores Adoption of Biosimilars in Oncology in Collaboration with Pfizer
National Comprehensive Cancer Network® (NCCN®)

National Comprehensive Cancer Network issues Request for Proposals (RFP) for projects that develop and validate enduring approaches to improve the safe, effective, and efficient adoption of biosimilars in oncology.

Newswise: Current Clinical Trial Assessing Potential of CBD in Treatment of Autism
Released: 14-Jul-2020 4:25 PM EDT
Current Clinical Trial Assessing Potential of CBD in Treatment of Autism
University of California San Diego Health

Researchers at University of California San Diego School of Medicine are recruiting eligible children between the ages of seven and fourteen years for a Phase III clinical trial to determine whether cannabidiol (CBD) reduces severe behavior problems in children with autism spectrum disorder.

Released: 14-Jul-2020 9:45 AM EDT
MD Anderson and Sanofi announce strategic collaboration to accelerate oncology research and development
University of Texas M. D. Anderson Cancer Center

The University of Texas MD Anderson Cancer Center and Sanofi today announced a five-year strategic collaboration to accelerate the development of investigational treatments, including targeted and immune therapies, for patients with cancer.

Newswise: Keck Medicine of USC enrolling patients as part of international clinical trial to study antiviral drug as treatment for COVID-19
Released: 14-Jul-2020 8:05 AM EDT
Keck Medicine of USC enrolling patients as part of international clinical trial to study antiviral drug as treatment for COVID-19
Keck Medicine of USC

Keck Medicine of USC physicians are enrolling patients as part of an international clinical trial to evaluate the safety and efficacy of an antiviral drug, DAS181, as a possible treatment for hospitalized patients with severe COVID-19.

Newswise: Study suggests lymphoma drug acalabrutinib might offer a potential therapeutic approach for severe COVID-19 infection
Released: 13-Jul-2020 3:45 PM EDT
Study suggests lymphoma drug acalabrutinib might offer a potential therapeutic approach for severe COVID-19 infection
Hackensack Meridian Health

The mechanisms of action of acalabrutinib led to the hypothesis it might be effective in reducing the massive inflammatory response seen severe forms of COVID19. Indeed, it did provide clinical benefit in a small group of patients by reducing their inflammatory parameters and improving their oxygenation.

Released: 13-Jul-2020 11:15 AM EDT
UTHealth joins study of blood pressure medication’s effect on improving COVID-19 outcomes
University of Texas Health Science Center at Houston

An interventional therapy aimed at improving survival chances and reducing the need for critical care treatment due to COVID-19 is being investigated by physicians at The University of Texas Health Science Center at Houston (UTHealth). The clinical trial is underway at Memorial Hermann and Harris Health System’s Lyndon B. Johnson Hospital.

Newswise: Does Blood Plasma from COVID-19 Survivors Help Patients Infected with Novel Coronavirus?
Released: 9-Jul-2020 4:05 PM EDT
Does Blood Plasma from COVID-19 Survivors Help Patients Infected with Novel Coronavirus?
University of California San Diego Health

Researchers at University of California San Diego School of Medicine and UC San Diego Health have launched a clinical trial to assess the safety and efficacy of convalescent plasma (CP) to prevent COVID-19 after a known exposure to the virus.

Newswise: Medical Cannabis put to the test in first ever real-world evidence clinical trial led by UHN
Released: 9-Jul-2020 5:00 AM EDT
Medical Cannabis put to the test in first ever real-world evidence clinical trial led by UHN
University Health Network (UHN)

Medical cannabis is finally being put under the microscope, in a first-of-its-kind real world evidence study led by Dr. Hance Clarke, Toronto General Hospital. In the Medical Cannabis Real-World Evidence trial patients using the online portal created by Medical Cannabis by Shoppers, will know exactly what is in their product and its effectiveness.

Newswise: Experimental drug shows early promise against inherited form of ALS, trial indicates
8-Jul-2020 8:55 AM EDT
Experimental drug shows early promise against inherited form of ALS, trial indicates
Washington University in St. Louis

A clinical trial conducted at Washington University School of Medicine in St. Louis and other sites has found evidence that the experimental drug tofersen lowers levels of a disease-causing protein in people with an inherited form of amyotrophic lateral sclerosis, or ALS, caused by mutations in the gene SOD1.

Newswise: University of Miami Miller School-led technology paves way for islet regeneration in human pancreas
Released: 8-Jul-2020 3:50 PM EDT
University of Miami Miller School-led technology paves way for islet regeneration in human pancreas
University of Miami Health System, Miller School of Medicine

New research published in Nature Communications uses a technology first developed at the University of Miami Miller School of Medicine to enhance the oxygenation of cultured tissues that will likely be able to conduct real-time regeneration and development studies in the human pancreas.

Newswise: A helping hand for cancer immunotherapy
7-Jul-2020 1:00 PM EDT
A helping hand for cancer immunotherapy
Sanford Burnham Prebys Medical Discovery Institute

Scientists at Sanford Burnham Prebys Medical Discovery Institute have demonstrated the therapeutic potential of PRMT5 inhibitors to sensitize unresponsive melanoma to immune checkpoint therapy. PRMT5 inhibitors are currently in clinical trials in oncology, and this research provides a strong rationale for evaluating the drugs in tumors that are not responsive to immune checkpoint therapy. The study was published in Science Translational Medicine.

Newswise: Mount Sinai Health System, Emergent BioSolutions, and ImmunoTek Bio Centers Form Collaboration to Develop Emergent’s COVID-19 Hyperimmune Globulin (COVID-HIG) Product Candidate with U.S. Department of Defense Funding
Released: 8-Jul-2020 9:00 AM EDT
Mount Sinai Health System, Emergent BioSolutions, and ImmunoTek Bio Centers Form Collaboration to Develop Emergent’s COVID-19 Hyperimmune Globulin (COVID-HIG) Product Candidate with U.S. Department of Defense Funding
Mount Sinai Health System

Mount Sinai and Emergent to conduct clinical trials to evaluate COVID-HIG for post-exposure prophylaxis of COVID-19 in front-line health care workers and to support a potential Expanded Access Program for military personnel with funding from the U.S. Department of Defense - ImmunoTek to extend operating license and provide training to Mount Sinai to establish onsite plasma collection to support production of COVID-HIG

Newswise: Seaver Autism Center For Research and Treatment at Mount Sinai Launches First Drug Trial for ADNP Syndrome
Released: 7-Jul-2020 1:55 PM EDT
Seaver Autism Center For Research and Treatment at Mount Sinai Launches First Drug Trial for ADNP Syndrome
Mount Sinai Health System

Researchers at the Seaver Autism Center for Research and Treatment at Mount Sinai have started recruiting participants for a new clinical trial to evaluate the safety, tolerability, and efficacy of a low dose of ketamine in children diagnosed with ADNP syndrome (also known as Helsmoortel-VanDerAa syndrome), a rare neurodevelopmental disorder caused by mutations in the activity dependent neuroprotective protein (ADNP) gene.

Newswise: Massachusetts Eye and Ear Enters Licensing Agreement with Biogen to Develop Treatment for Inherited Retinal Disorder
2-Jul-2020 8:00 AM EDT
Massachusetts Eye and Ear Enters Licensing Agreement with Biogen to Develop Treatment for Inherited Retinal Disorder
Massachusetts Eye and Ear

Massachusetts Eye and Ear, a member hospital of Mass General Brigham, is entering into an exclusive licensing agreement with Biogen to develop a potential treatment for inherited retinal degeneration due to mutations in the PRPF31 gene, which are among the most common causes for autosomal dominant retinitis pigmentosa.

Newswise: 236360_web.jpg
Released: 1-Jul-2020 12:40 PM EDT
Clinical-grade wearables offer continuous monitoring for COVID-19
Northwestern University

Stamp-sized device comprises a suite of clinical-grade sensors, including temperature and pulse oximetry

Newswise: Study Validates Combination Therapy for Aggressive Endometrial Cancer
26-Jun-2020 12:45 PM EDT
Study Validates Combination Therapy for Aggressive Endometrial Cancer
Yale Cancer Center

Yale Cancer Center (YCC) scientists have found that combining the targeted drug trastuzumab with chemotherapy significantly improves survival rates for women with a rare, aggressive form of endometrial cancer.


Showing results

150 of 577

close
2.63186